Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations: 2013-2024

Historic Income from Continuing Operations for Summit Therapeutics (SMMT) over the last 12 years, with Dec 2024 value amounting to -$234.7 million.

  • Summit Therapeutics' Income from Continuing Operations fell 81.23% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 94.97%. This contributed to the annual value of -$234.7 million for FY2024, which is 61.84% up from last year.
  • As of FY2024, Summit Therapeutics' Income from Continuing Operations stood at -$234.7 million, which was up 61.84% from -$614.9 million recorded in FY2023.
  • In the past 5 years, Summit Therapeutics' Income from Continuing Operations ranged from a high of -$52.7 million in FY2020 and a low of -$614.9 million during FY2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$234.7 million (2024), whereas its average is -$309.5 million.
  • In the last 5 years, Summit Therapeutics' Income from Continuing Operations crashed by 680.54% in 2023 and then skyrocketed by 61.84% in 2024.
  • Over the past 5 years, Summit Therapeutics' Income from Continuing Operations (Yearly) stood at -$52.7 million in 2020, then crashed by 68.13% to -$88.6 million in 2021, then climbed by 11.08% to -$78.8 million in 2022, then plummeted by 680.54% to -$614.9 million in 2023, then spiked by 61.84% to -$234.7 million in 2024.